Failure of myeloma cells to undergo apoptosis plays an important role in the accumulation of myeloma cells within the bone marrow (BM). Moreover, inhibition of drug-induced apoptosis has been indicated as a major contributor of drug resistance in myeloma. The BM microenvironment promotes survival and blocks the apoptotic effects of various cytotoxic agents through the production of cytokines as well as through direct physical interactions. Several antiapoptotic proteins and antiapoptotic signaling cascades have been identified that contribute to the antiapoptotic phenotype of the myeloma cell. In this review, we discuss mechanisms that result in enhanced survival and drug resistance of myeloma cells. Insight into these mechanisms is essential to make progress in the therapy of myeloma.
Introduction
Multiple myeloma is characterized by the accumulation of monoclonal plasma cells in the bone marrow (BM). The neoplastic cells are long-lived cells with a low proliferative index. Several antiapoptotic proteins and antiapoptotic signaling cascades contribute to the accumulation of myeloma cells within the BM by preventing normal cell turnover caused by physiological cell death mechanisms. 1 Moreover, since cytotoxic agents induce cell death through the triggering of apoptosis, 1 inhibition of drug-induced apoptosis has been suggested as a major contributor of drug resistance in myeloma. Here, we review mechanisms that contribute to enhanced survival and drug resistance of myeloma cells. Insight into these mechanisms is essential to make progress in the therapy of myeloma.
Growth factors and adhesion molecules
Interaction of myeloma cells with cells within the BM microenvironment results in the production of diverse cytokines and growth factors. Furthermore, direct physical interactions with bone marrow stromal cells (BMSCs) or extracellular matrix molecules prevent myeloma cells from apoptosis induced by anticancer agents (Figure 1 ). [2] [3] [4] [5] [6] Interleukin-6 (IL-6) is one of the most important growth factors for myeloma cells, and is predominantly produced by BMSCs, but also by activated osteoclasts. 7 Adhesion of myeloma cells to BMSCs resulting in the activation of signaling pathways including NF-kB and Notch-1 pathways, 8, 9 and soluble factors produced by myeloma cells such as tumor necrosis factor-a (TNF-a), transforming growth factor-b (TGF-b), interleukin-1b (IL-1b), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) stimulate IL-6 secretion in BMSCs. 10, 11 Conversely, IL-6 enhances the production and secretion of bFGF and VEGF by myeloma cells. 10, 11 In addition, to paracrine production by cells in the BM microenvironment, IL-6 is also produced in an autocrine way by the myeloma cells themselves. 12 IL-6 induces myeloma cell proliferation, inhibits apoptosis, and overrides the apoptotic signals mediated by cytotoxic drugs. 13 Binding of IL-6 to the IL-6 receptor triggers the activation of at least three signaling pathways; the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway, 14 the Ras/ mitogen-activated protein kinase (MAPK) pathway, 15 and the phosphatidylinositol-3 kinase (PI-3K) pathway. 16 Activation of the JAK/STAT3 14, 17 and PI-3K pathways 18 is implicated in protection against apoptosis, whereas activation of the Ras-MAPK, 15 JAK/STAT3 14, 19 and PI-3K pathways 18 induces proliferation.
Insulin-like growth factor-I (IGF-I) is also an important growth factor for myeloma cells and stimulates proliferation of both IL-6-independent and -dependent cell lines, and protects myeloma tumor cells against serum starvation and death induced by dexamethasone. 16, 20 IGF-I may act synergistically with IL-6 on myeloma cell growth and survival. 21 IGF-I stimulation leads to activation of both the MAPK and the PI-3K pathways, but the PI-3K pathway was demonstrated to be the major regulator of both apoptosis and proliferation, with only minimal contributions to either by the MAPK cascade. 20, 22 In myeloma, it has also been demonstrated that activation of the PI-3K/AKT pathway by IGF-I induces NF-kB activation. 23 IGF-I is produced in the liver and by a number of cell types in the BM microenvironment including BMSCs, osteoblasts, and endothelial cells. 24 Other growth factors for myeloma cells include VEGF, bFGF, and WNT family members, which are produced by myeloma cells 11, 25, 26 and BMSCs. 11, 26 Treatment of myeloma cells with bFGF induces proliferation and partially protects them from apoptosis. 27 Several studies have shown that VEGF enhances myeloma cell survival through the upregulation of various antiapoptotic proteins (such as Mcl-1, survivin, and cIAP), 27, 28 increases resistance to dexamethasone, 29 and induces proliferation via the activation of the Raf-MEK-extracellular-signalregulated protein kinase (ERK) pathway. [27] [28] [29] [30] In addition, the pan-VEGF receptor inhibitor GW654652 significantly decreased myeloma cell proliferation and survival. 30 WNT signaling results in the accumulation of unphosphorylated active b-catenin, which translocates to the nucleus and contributes to myeloma cell proliferation. 26 Drug resistance induced by adhesion (cell adhesion-mediated drug resistance; CAM-DR) of myeloma cells to fibronectin is associated with activation of NF-kB and increased expression of antiapoptotic proteins. 31 BMSCs contribute to CAM-DR through several mechanisms including direct interaction with myeloma cells, and the effects of soluble factors generated by cell-cell interaction. 5, 6 The most important adhesion molecules, which mediate contact between myeloma cells and stromal cells, are LFA-1 and VLA-4 on myeloma cells and VCAM-1 and ICAM-1 on stromal cells. These adhesion molecules are upregulated on treatment with cytotoxic drugs. 2, 6 Furthermore, adhesion molecules such as VLA-4 are overexpressed in drug-resistant myeloma cell lines.
2 Targeting LFA-1 and VLA-4 by monoclonal antibodies or small molecular drugs reduced CAM-DR in myeloma cell lines, 6 and disruption of the interactions between VLA-4 and VCAM-1 using a VLA-4 monoclonal antibody suppressed the development of multiple myeloma in a mouse model. 32 Interaction with BMSCs activates Notch-1 signaling in myeloma cells, which results in significant protection of myeloma cells from melphalan-and mitoxantrone-induced apoptosis. 33 
Ras
In myeloma cells, IL-6 triggers the transition of Ras from the inactive GDP-bound form to the active GTP-bound form and activates the MAPK pathway, leading to proliferation. 15, 34 This suggests that Ras transduces proliferation signals through activation of the Raf-MAPK pathway, but Ras proteins are also involved in the transduction of survival and growth signals through pathways such as PI-3K/AKT and NF-kB. 35 The frequency of activating Ras mutations is 39% in patients with newly diagnosed disease, 36 and increases to 64-70% in patients with advanced disease. 37 Furthermore, Ras mutations are absent in patients with MGUS. 38 This suggests that mutations of Ras represent a progression event and not an initiating event. The presence of Ras mutations at diagnosis is associated with an adverse outcome, a poor response to therapy, 37 and a shorter survival. 36 In vitro studies showed that Ras mutations are associated with IL-6-independent growth, 39 and provide resistance against apoptosis induced by cytotoxic agents such as dexamethasone, doxorubicin, and melphalan 39, 40 through the constitutive activation of MAPK, PI-3K, and NF-kB signaling pathways. 35 
Nuclear factor-jB
In most cell types, NF-kB resides in the cytosol and is inactivated by its association with IkB family inhibitors. Activators of NF-kB such as TNF-a activate IkB kinase (IKK), leading to the phosphorylation and subsequent degradation of IkB by the 26S proteasome. The direct consequence is the translocation of NF-kB from the cytoplasm into the nucleus, leading to transcription of target genes. Various reports have Growth factors and adhesion of myeloma cells to BMSCs activate signaling pathways leading to myeloma cell proliferation, survival, and resistance to cytotoxic agents. Interaction of myeloma cells with BMSCs leads to the production of diverse growth factors, which activate various signaling pathways. Furthermore, direct physical interaction between myeloma cells and BMSCs results in drug resistance.
Antiapoptotic signaling pathways in myeloma NWCJ van de Donk et al indicated constitutive activity of NF-kB in myeloma cells from patients and in myeloma cell lines. [41] [42] [43] Diminished NF-kB activity is an early event in dexamethasone-induced apoptosis and maintenance of constitutive activity of NF-kB correlates with resistance of myeloma cell lines to dexamethasone. 41 Furthermore, thalidomide also possesses anti-NF-kB activity. 44 Specific inhibition of NF-kB activity induces apoptosis, inhibits proliferation, potentiates the cytotoxic effects of chemotherapeutic agents, and abrogates the protective effect of IL-6 on dexamethasone-and thalidomide derivatives-induced growth inhibition. 42, 43, 45, 46 Furthermore, both adhesion of myeloma cells to BMSCs and TNF-a secreted by myeloma cells trigger the transcription and secretion of the important growth and survival factor IL-6 in BMSCs through the activation of NF-kB. 8, 43, 47 In myeloma cell lines, the proteasome inhibitor bortezomib has been shown to induce apoptosis, to inhibit proliferation, and to sensitize myeloma cells to conventional chemotherapeutic agents, which was, at least in part, due to inhibition of NF-kB activity by blocking the degradation of IkB. 45 Clinical studies have shown that bortezomib has activity against refractory multiple myeloma. 48 
PI-3K/AKT pathway
Activation of PI-3K results in the generation of phosphatidylinositol (PI) phosphates including PIP 3 . One target of PI-3K and the phospholipids is AKT. The phospholipid molecules bind to the pleckstrin-homology domain of AKT, resulting in its translocation to the cell membrane, where its activation occurs through phosphorylation by PDK 1 and 2. Constitutive activation of PI-3K and AKT was found in myeloma cell lines 16 and in myeloma cells from patients, whereas AKT activation was not observed in nonmalignant hematopoietic cells from the same patients. 16, 49 Several studies have shown that various myeloma growth and survival factors including IL-6, bFGF, VEGF, and IGF-I can activate the PI-3K/AKT pathway in myeloma cells. 16, 18, 22, 27, 50 These growth factors may therefore contribute to the activation of the PI-3K/AKT pathway in myeloma cells in vivo. However, loss of PTEN expression may also contribute to uncontrolled AKT activity in myeloma. 50 The tumor suppressor PTEN dephosphorylates PI-3K products such as PIP 3 and leads to a concomitant reduction in AKT activity. Induction of proliferation, survival, and protection against cytotoxic agents mediated by IGF-I and IL-6 are, at least in part, dependent on the activation of a PI-3K-dependent pathway. 16, 18, 22 Activation of AKT by PI-3K may be responsible for the proliferative and antiapoptotic effects of PI-3K, since expression of a dominantnegative AKT gene in myeloma cells or pharmacologic inhibition of AKT resulted in a decreased number of cells in S phase and increase in apoptosis. 23, 49 Furthermore, the AKT inhibitor restored sensitivity of myeloma cells to Apo2L/TRAIL. 23 In addition, expression of constitutively active AKT protected myeloma cells against both novel and conventional antitumor agents including doxorubicin. 23 Downstream targets of AKT that are involved in the control of survival and proliferation of myeloma cells include Bad, p70 S6K , the translational repressor eukaryotic initiation factor (eIF) 4E binding protein (4E-BP1) NF-kB, and the Forkhead family members 18, 22, 23, 27, 35, 50, 51 ( Figure 2) . In myeloma cells, PI-3K/AKT signaling-induced phosphorylation and activation of the serine/threonine kinase p70 S6K and phosphorylation of 4E-BP1 is mediated via the mammalian target of rapamycin (mTOR). 51 Inhibition of mTOR by rapamycin inhibits myeloma cell proliferation, induces apoptosis, and sensitizes myeloma cells to dexamethasoneinduced apoptosis. 22, 51, 52 AKT activation also results in phosphorylation of the Forkhead transcription factors FKHR, FKHRL-1, and AFX, which prevents its nuclear translocation and transcriptional activity. 18, 22, 23, 27 This contributes to myeloma cell proliferation and the protective effect of IGF-I against dexamethasone-induced apoptosis. 22 Furthermore, it is possible that AKT modulates myeloma cell growth and survival via phosphorylation of MDM2, which leads to inhibition of the nuclear localization of p53 with related decrease in expression of p53 target genes including Bax and p21
Cip1/Waf1 .
21
JAK/STAT pathway STAT3 has been shown to be constitutively active in part of myeloma cell lines and in the majority of myeloma cells from patients, whereas plasma cells from healthy individuals were not. 17, 43 In myeloma, IL-6 is a potent activator of STAT3.
14 Binding of IL-6 to the IL-6 receptor induces recruitment and activation of tyrosine kinases of the JAK family. These JAK proteins, in turn, phosphorylate tyrosine residues of the receptor chain, which then serve as docking sites for STAT3 proteins. After phosphorylation of STAT3 proteins by JAK proteins, STAT3 proteins dimerize and translocate from the cytoplasm to the nucleus, where they initiate the transcription of target genes implicated in myeloma cell survival including Bcl-XL and Mcl-1, and proliferation including cyclin D1. 17, 19, 53 SOCS-1 and SHP1 are negative regulators of the JAK/STAT pathway and frequently silenced by hypermethylation in myeloma cells, which may contribute to activation of the JAK/STAT3 pathway. 54, 55 STAT3 plays an important role in myeloma cell survival, 14, 17 chemoresistance, 17, 56 and proliferation. 14, 19 However, in the presence of BMSCs survival of myeloma cells becomes independent of IL-6-induced STAT3 signaling. 4 
Bcl-2
The Bcl-2 family consists of proapoptotic (Bax, Bak, Bid, Bcl-XS, Bad, Bik, Bim, and Hrk) and antiapoptotic (Bcl-2, Bcl-XL, Bcl-W, Bfl-1/A1, and Mcl-1) family members. The ratio of antiand proapoptotic Bcl-2 family proteins determines whether a cell will survive or die after an apoptotic signal. Antiapoptotic Bcl-2 family members are localized in the mitochondrial outer membrane, nuclear membrane, or the endoplasmic reticulum. 57 A substantial fraction of the proapoptotic Bcl-2 family members, however, reside in the cytosol or localize to the cytoskeleton. 57 Following a death signal, these proapoptotic proteins undergo a change of conformation and translocate to mitochondria. It is hypothesized that following translocation of proapoptotic proteins to mitochondria, the activity of the antiapoptotic Bcl-2 family members is neutralized through the formation of heterodimers leading to release of multiple apoptogenic proteins including cytochrome c from the mitochondrial intermembrane space. 57 Cytosolic cytochrome c binds to Apaf-1 and induces caspase-9-dependent activation of caspase-3. This culminates in cleavage of key proteins, leading to cell death.
Several studies have demonstrated high levels of Bcl-2 expression in both normal BM plasma cells and malignant plasma cells derived from patients with myeloma. [58] [59] [60] The t(14;18) (q32;q21) translocation, which results in the juxtaposition of Bcl-2 normally located on chromosome 18 with transcriptional enhancer regions in 14q32, is not present in myeloma cells. This indicates that other mechanisms such as hypomethylation of the Bcl-2 gene, constitutive activity of NFkB which induces Bcl-2 transcription, 42, 46 or loss of the p53 tumor suppressor which inhibits Bcl-2 gene expression, 61 may be involved (Figure 3) . In myeloma, the prognostic significance of Bcl-2 expression is currently unclear. In three studies, no correlation between Bcl-2 expression and both response to chemotherapy and survival was observed. [58] [59] [60] One study showed that high levels of Bcl-2 expression are associated with resistance to interferon therapy. 58 Overexpression of Bcl-2 in B cells through use of an immunoglobulin gene enhancer in transgenic mice prolonged the life span of plasma cells and B cells, 62 and in combination with abnormal expression of other oncogenes such as c-Myc, contributed to the development of plasmacytoma, immature pre-B cell lymphoma, or large cell lymphoma in the mice. 63 Expression of Bcl-2 abrogates c-Mycinduced apoptosis without affecting the c-Myc mitogenic function. 64 This provides an explanation for the ability of Bcl-2 to synergize with c-Myc in cell transformation.
There are several lines of evidence that suggest that Bcl-2 plays a role in drug resistance in myeloma. Bcl-2 overexpression in myeloma cells using gene transfer approaches has been shown to confer resistance to chemotherapeutic agents including dexamethasone, etoposide, doxorubicin, and bortezomib, 41, [65] [66] [67] and to protect against IL-6 deprivation-induced apoptosis. 68 In addition, Bcl-2 protein levels increased following exposure of cell lines to doxorubicin, which may account for the relative resistance to a second doxorubicin exposure. 65 Treatment of myeloma cells with Bcl-2 antisense oligodeoxynucleotides (ODNs) led to a sequence-specific decrease in Bcl-2 protein levels, which was followed by enhanced sensitivity of myeloma tumor cells to dexamethasone or doxorubicin-induced apoptosis (Figure 4) . 69, 70 Furthermore, exposure of myeloma cell lines to bortezomib followed by the small molecule Bcl-2 inhibitor HA14-1 resulted in a marked increase in apoptosis. 71 Two phase 2 clinical trials have suggested that Bcl-2 antisense (G3139) may potentiate the activity of the combination of vincristine, adriamycin, and dexamethasone (VAD) 72 and the combination of dexamethasone and thalidomide 73 in patients with resistant myeloma. However, a randomized phase 3 clinical study has shown that addition of G3139 to dexamethasone did not increase the time to progression or response rate in refractory and relapsed myeloma patients. 74 Other novel agents such as NF-kB inhibitors 46 and arsenic trioxide 75 induce myeloma cell apoptosis at least in part through downregulation of Bcl-2.
Bcl-XL
Bcl-XL is expressed in myeloma cells. In part of the myeloma cell lines, Bcl-XL expression is induced by IL-6 through STAT3-dependent pathways (Figure 3) . 17, 68, 76 Inhibitors of STAT3 activation rendered drug-resistant myeloma tumor cells sensitive to drug-mediated apoptosis 56 and enhanced susceptibility to Fas-mediated apoptosis. 17, 19 The sensitization correlated with the inhibition of Bcl-XL expression. 17, 19, 56 The t(4;14)(p16;q32.3) translocation is identified in approximately 15% of myeloma patients, and results in aberrant expression of fibroblast growth factor receptor 3 (FGFR3). FGFR3-overexpressing myeloma cells exhibit decreased apoptosis on IL-6 withdrawal and become chemoresistant to dexamethasone, at least in part through the STAT3-mediated upregulation of Bcl-XL (Figure 3) . 77 Finally, suppression of constitutive NF-kB activity by NF-kB inhibitors reduced the expression of several gene products regulated by NF-kB including Bcl-XL (Figure 3) . 42 This was associated with induction of apoptosis, and enhancement of the cytotoxic effects of chemotherapeutic agents. 42 Transgenic mice that express a Bcl-XL transgene in mature B cells and plasma cells developed nonmalignant BM and extramedullary plasma cell foci. When Bcl-XL and c-Myc were coexpressed, highly fatal plasma cell malignancies developed rapidly and with full penetrance. C-Myc transgenic mice also developed neoplasms, but tumor development took a long time and occurred with low penetrance. 78 It is likely that protection from c-Myc-induced apoptosis is a critical component of Bcl-XL's ability to promote plasma cell tumor formation in c-Myc/ Bcl-XL mice. 78 Ectopic overexpression of Bcl-XL increased the resistance of a myeloma cell line to various cytotoxic drugs including the topoisomerase II inhibitor doxorubicin and the alkylating agent melphalan. 19 Bcl-XL appears to be upregulated in specimens taken from patients at the time of relapse, when compared to expression levels at initial diagnosis. 79 In addition, Bcl-XL expression correlates with decreased response rates in patient groups treated with either melphalan and prednisone or with vincristine, adriamycin, and dexamethasone. 79 However, a recent study using antisense technology demonstrated that downregulation of Bcl-XL protein expression in myeloma cell lines did not induce apoptosis or enhance chemosensitivity, 70 suggesting that Bcl-XL is not involved in drug resistance in myeloma. Altogether, further research is warranted to accurately define the role of Bcl-XL in survival and drug resistance in multiple myeloma.
Mcl-1
Mcl-1 has a short half-life, when compared with other Bcl-2 family members, like Bcl-2 or Bcl-XL. In normal cells, Mcl-1 expression is rapidly upregulated during critical events such as changes in proliferation, cellular stress, and differentiation, suggesting that its function is to provide short-term, rapidly inducible enhancement of cell viability. 80 However, deregulated or constitutive expression of Mcl-1, as opposed to the transient expression in normal cells, may result in enhanced survival over the long term and tumorigenic conversion and may attribute to resistance of tumor cells to cytotoxic drugs.
Mcl-1 is overexpressed in myeloma cells, when compared with normal plasma cells. 81, 82 Moreover, Mcl-1 expression is higher at the time of relapse and increased Mcl-1 expression is associated with a significantly shorter event-free survival of myeloma patients. 83 Various studies have shown that IL-6 is the main cytokine that upregulates Mcl-1 expression in myeloma cells (Figure 3) . 14, 28, 53, 76, 84 The JAK/STAT3 signal transduction pathway seems to be responsible for the increased expression of Mcl-1 by IL-6. 53 Constitutive Mcl-1 expression strongly reduces apoptosis induced by IL-6 withdrawal, indicating that IL-6-induced survival is mediated, at least in part, through Mcl-1 upregulation.
14,84 However, Zhang et al 85 demonstrated that in the majority of myeloma cell lines and myeloma patients' samples, Mcl-1 regulation is IL-6-independent and not controlled by the JAK/STAT3, MAPK, or PI-3K signaling pathways. Interruption of the NF-kB pathway results in diminished Mcl-1 expression, possibly in a c-Jun N-terminal kinase (JNK)-dependent way, which may contribute to the induction of apoptosis (Figure 3) . 86 VEGF has also been demonstrated to upregulate Mcl-1 protein expression in myeloma cells. This may account, at least in part, for the antiapoptotic effect of VEGF in multiple myeloma (Figure 3) . 28 In addition, the recently identified myeloma growth factors B-cell activating factor Bcl-2 antisense ODNs potentiate drug-induced apoptosis. Bcl-2 antisense-mediated downregulation of Bcl-2 protein levels restores sensitivity to cytotoxic agents in myeloma cells.
(BAFF) and a proliferation-inducing ligand (APRIL) activate NFkB, PI-3K/AKT, and MAPK pathways in myeloma cells and induce a strong upregulation of Mcl-1 and Bcl-2 leading to rescue of myeloma cells from apoptosis induced by dexamethasone and IL-6 deprivation ( Figure 3) . 87 Protein expression of Mcl-1 also increases by adherence of myeloma cells to BMSCs. 88 Conversely, downregulation of Mcl-1 by antisense oligonucleotides or siRNA induces apoptosis in myeloma cells, 28, 70 sensitizes myeloma cells towards cytotoxic agents, 70 and inhibits myeloma cell proliferation. 28 Various novel biologic agents like cyclin-dependent kinase inhibitors, 88 statins, 89 and NF-kB inhibitors 86 induce apoptosis in myeloma cells, at least in part, by downregulating Mcl-1. Taken together, these data provide evidence that Mcl-1 can contribute to increased survival, enhanced proliferation, and chemotherapeutic resistance of myeloma cells.
Proapoptotic Bcl-2 family proteins in myeloma
Various proapoptotic Bcl-2 family members are expressed in myeloma cells. Bax is expressed in both malignant and in nonneoplastic plasma cells. 81 Quantitative analysis revealed that the malignant phenotype correlates with a decreased expression of Bax and an increased Bcl-2/Bax expression ratio, 81 which may contribute to reduced sensitivity of myeloma cells to anticancer agents. However, a recent investigation showed that expression of Bax did not correlate with responsiveness to chemotherapy or duration of response. 60 In myeloma methylation of DNA has been shown to decrease the expression of several genes including the proapoptotic Bcl-2 family proteins Bad, Bak, Bik, and Bax. 90 Drugs that inhibit DNA methylation may be useful for treating resistant or relapsing myeloma.
Various pro-and antiapoptotic stimuli modulate the expression or the activity of proapoptotic Bcl-2 family proteins. In myeloma cells, the onset of doxorubicin-induced apoptosis correlates with the appearance of the active conformations of the proapoptotic Bcl-2 family proteins Bak and Bax. 66 Bak-or Bax-deficient cells are resistant to doxorubicin-induced apoptosis. 66 Radiation-induced apoptosis is also associated with moderate changes in cytosol-to-mitochondria Bax redistribution. 91 Inhibition of NF-kB activity by the cell-permeable inhibitor SN50 resulted in a decrease in Bcl-2 and A1 and an upregulation of Bax protein levels, shifting the balance toward apoptosis. 46 Furthermore, IL-6-deprivation-induced apoptosis is associated with increased expression of Bax. 81 Activated PI-3K inhibits apoptosis and renders multiple myeloma cells resistant to various chemotherapeutic drugs. One mechanism involves the phosphorylation and inactivation of the forkhead group of transcription factors. 18, 22 Forkhead proteins are able to induce the expression of the proapoptotic Bcl-2 family member Bim. Myeloma cells adhered to fibronectin are protected from melphalan-induced apoptosis, which is mediated at least in part by transcriptional repression of Bim. 3 The possible role of PI-3K in this pathway remains to be identified. Furthermore, IGF-I and IL-6 signaling through PI-3K and AKT protect myeloma cells from apoptosis, at least in part, by the phosphorylation and inactivation of the proapoptotic Bcl-2 family protein Bad 18 ( Figure 2 ). Caspase-8 cleaves Bid to its active proapoptotic truncated form (tBid), which targets mitochondria and induces cytochrome c release. 57 Doxorubicin treatment leads to the cleavage of Bid in a caspase-8-dependent manner; however, the contribution of Bid cleavage to doxorubicin-induced apoptosis of myeloma cells seems to be minor. 66 Cleavage of Bid was also detected in myeloma cells treated with a histone deacetylase inhibitor, 92 interferon-a, 93 and arsenic trioxide, 94 suggesting a possible role for Bid in regulation of cell death induced by these agents.
In myeloma cells, various apoptotic stimuli 89, 91, 93 result in the caspase-3-mediated cleavage of Bcl-2 into the 23 kDa proapoptotic Bcl-2 form, which localizes to mitochondria and stimulates the release of cytochrome c into the cytosol. 57 Therefore, cleavage of Bcl-2 in myeloma appears to promote further caspase activation as part of a positive feedback loop. Bcl-XS and Mcl-1S are proapoptotic Bcl-2 family proteins that arise through alternate splicing of Bcl-X and Mcl-1, respectively. Bcl-XS is not or only weakly expressed in myeloma cells. 79, 84 R-etodolac-induced myeloma cell apoptosis correlates with upregulation of Mcl-1S. 95 
Mevalonate pathway
The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase is the rate-limiting enzyme of the mevalonate pathway and catalyzes the reduction of HMG-CoA to mevalonate, which is an intermediate in the synthesis of various substances including cholesterol and the isoprenoid molecules farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP). 96 These isoprenoids are used for posttranslational modification of a variety of proteins, including Ras and Rho family proteins. Farnesyl transferase (FTase) catalyzes the transfer of a farnesyl group from FPP (farnesylation), whereas geranylgeranyl transferases (GGTase) I and II catalyze the transfer of a geranylgeranyl moiety derived from GGPP (geranylgeranylation) to cysteines at the carboxy-terminus of the protein. Isoprenylation is essential for proper cellular localization and participation of the modified proteins in signal transduction processes. 96 In myeloma, drug resistance mediated by adhesion of tumor cells to fibronectin via b1 integrins or by chronic drug exposure is associated with an increase in several enzymes including HMG-CoA reductase. 3 Suppression of the mevalonate pathway through the inhibition of HMG-CoA reductase by statins inhibits myeloma cell proliferation, 97, 98 induces apoptosis, 89, 97 and restores chemosensitivity. 6, 97 These effects are mediated by depletion of GGPP leading to inhibition of protein geranylgeranylation. 6, 89, 98 In addition, inhibition of GGTase I activity reduces proliferation and induces apoptosis, with only small effects of inhibition of FTase. 4, 35, 89, 98 The increased sensitivity of myeloma cells to chemotherapeutic drugs by inhibition of geranylgeranylation either by depletion of GGPP or inhibition of GGTase I activity may be due to downregulation of Mcl-1 protein levels 89 as well as inhibition of Rho-associated kinase. 6 In myeloma cells, induction of apoptosis and inhibition of proliferation by nitrogen-containing bisphosphonates is also mediated by the depletion of GGPP through inhibition of farnesyl diphosphate synthase, an enzyme of the mevalonate pathway. 99, 100 These data suggest that modulation of the mevalonate pathway represents a novel therapeutic approach in the treatment of myeloma.
Future directions
The identification and increased understanding of mechanisms that regulate survival, drug resistance, and proliferation will contribute to the development of new specific and effective therapeutic strategies to modulate apoptosis, growth, and drug resistance in multiple myeloma. With rare exceptions, malig-nant cell growth is the result of multiple genetic alterations. The combination of novel agents that simultaneously target a single pathway or that target different pathways will therefore be critical to avoid drug resistance and to achieve long-term remissions. The introduction of novel agents together with technologies such as gene expression profiling to identify those patients who are most likely to respond, will result in a more selective and potent molecular-based myeloma therapy that will improve patient outcome.
